Top in hem/onc: Red meat and colorectal cancer risk, decline in cancer screenings
Click Here to Manage Email Alerts
An alkylating mutational signature in colon cells appeared to be associated with red meat consumption and certain cancer driver mutations, according to a recent study. An interview with one of the authors was the top story in hematology/oncology last week.
Also, the CDC reported large declines in breast and cervical cancer screenings during the first few months of the COVID-19 pandemic. The trends varied by region, race/ethnicity and rural vs. urban settings, with non-white women experiencing the highest decline in screening.
Read these and more top stories in hematology/oncology below:
’Mounting’ data link red meat consumption to colorectal cancer risk, mortality
Researchers have identified a possible molecular link between high consumption of both processed and unprocessed red meat and increased colorectal cancer risk and mortality. Read more.
CDC reports 80% declines in breast, cervical cancer screenings during start of pandemic
Breast cancer and cervical cancer screenings declined sharply during the early part of the COVID-19 pandemic, according to CDC data released today. Read more.
Women in Oncology Peer Perspective Board addresses sexual misconduct in health care
Considering the number of women and men who report sexual harassment within health care, members of the Women in Oncology Peer Perspective Board called for a “top-down approach to change the system to one that is not only equitable and fair, but also punishes people who behave and act in a manner that is not appropriate for anyone in society.” Read more.
Convalescent plasma shows survival benefit for patients with blood cancer, COVID-19
Convalescent plasma treatment appeared to be associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology. Read more.
FDA grants fast track designation to SNDX-5613 for acute leukemia
The FDA granted fast track designation to SNDX-5613 for the treatment of adults and children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia with certain genetic markers. Read more.